r-n-jРоссийский неврологический журналRussian neurological journal2658-79472686-7192МИА10.30629/2658-7947-2021-26-5-44-50r-n-j-227Research ArticleКЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ И НАБЛЮДЕНИЯCLINICAL RESEARCH AND SURVEILLANCEПрименение Эренумаба у пациентов с хронической мигренью в реальной клинической практикеThe use of the monoclonal antibody Erenumab in patients with chronic migraine in real clinical experiencehttps://orcid.org/0000-0002-3638-6094ЕкушеваЕ. В.EkushevaE. V.

Москва; Белгород

Moscow; Belgorod

ekushevaev@mail.ruАртеменкоА. Р.ArtemenkoA. R.

Москва

Moscow

https://orcid.org/0000-0002-3557-5424ШиршоваЕ. B.ShirshovaE. V.

Москва

Moscow

https://orcid.org/0000-0002-2365-5128СоковП. Е.SokovP. E.

Москва

Moscow

ПлиеваА. М.PlievaA. M.

Москва

Moscow

Академия постдипломного образования ФГБУ «Федеральный научно-клинический центр специализированных видов медицинской помощи и медицинских технологий Федерального медико-биологического агентства»; ФГАОУ ВО «Белгородский государственный национальный исследовательский университет»РоссияAcademy of Postgraduate Education of the Federal Scientific and Clinical Center for Specialized Types of Medical Care and Medical Technologies of the Federal Medical and Biological Agency of Russia; Belgorod State National Research UniversityRussian FederationИПО Первый Московский государственный университет им. И.М. Сеченова Минздрава РоссииРоссияI.M. Sechenov First Moscow State Medical UniversityRussian FederationАкадемия постдипломного образования ФГБУ «Федеральный научно-клинический центр специализированных видов медицинской помощи и медицинских технологий Федерального медико-биологического агентства»РоссияAcademy of Postgraduate Education of the Federal Scientific and Clinical Center for Specialized Types of Medical Care and Medical Technologies of the Federal Medical and Biological Agency of RussiaRussian FederationГКБ им. В.В. Виноградова Департамента здравоохранения МосквыРоссияCity Clinical Hospital named after Vinogradov V.V. of the Moscow City Health DepartmentRussian Federation2021111120212654450Copyright © Екушева Е.В., Артеменко А.Р., Ширшова Е.B., Соков П.Е., Плиева А.М., 20212021Екушева Е.В., Артеменко А.Р., Ширшова Е.B., Соков П.Е., Плиева А.М.Ekusheva E.V., Artemenko A.R., Shirshova E.V., Sokov P.E., Plieva A.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.r-n-j.com/jour/article/view/227

Пациенты с хронической мигренью (ХМ) характеризуются частыми приступами интенсивной головной боли (ГБ), избыточным применением обезболивающих средств, недостаточным эффектом превентивной терапии и снижением качества жизни.

Целью проспективного открытого исследования было изучение эффективности и переносимости Эренумаба (Иринэкса) при лечении пациентов с ХМ в реальной клинической практике.

Материал и методы

Материал и методы. Клинически и неврологически обследовано 48 пациентов с ХМ (35,5 [19; 56], диагноз которым устанавливался согласно критериями международной классификации ГБ. Продолжительность наблюдения составила 3 мес., в течение которых 1 раз в месяц проводилось клинико-неврологическое тестирование и подкожное введение препарата Эренумаб (Иринэкс) 70 мг.

Результаты

Результаты. Показана безопасность, хорошая переносимость и очевидный существенный клинический эффект при использовании Эренумаба (Иринэкса) 70 мг, который привел у большинства пациентов к значимому улучшению клинических показателей и течения ХМ, повышению эффективности купирования ГБ и существенному сокращению приема обезболивающих лекарственных средств, причем через 3 мес. терапии отмечались наилучшие результаты.

Patients with chronic migraine are characterized by frequent severe headache attacks, polypharmacy (painkillers), insufficient effect of preventive therapy, and a decrease in the quality of life. The aim of a prospective open-label study was the evaluation of the efficacy and tolerance of Erenumab (Irinex) in the treatment of patients with chronic migraine in real clinical practice.

Material and methods

Material and methods. 48 patients with chronic migraine were clinically and neurologically examined (35.5 [19; 56]; diagnosis was established according to the criteria of ICHD classification and diagnosis of migraine. Medical monitoring period was 3 months. Clinical and neurological testing and subcutaneous administration of Erenumab (Irinex) 70 mg were performed once a month during the whole period.

Results

Results. Safety, good tolerance and an obvious significant clinical effect were noted when using Erenumab (Irinex) 70 mg. It led to a significant improvement in clinical score and the course of chronic migraine, the effectiveness of rapid relief of symptoms and significant reduction in the need for painkillers in most patients. The best results were found after 3 months of therapy.

моноклональные антителаЭренумабмигреньхроническая мигреньрезистентнаярефрактерная мигреньголовная болькальцитонин ген-родственный пептидmonoclonal antibodiesErenumabmigrainechronic migraineresistantrefractory migraineheadachecalcitonin gene-related peptideReferencesSteiner T.J., Birbeck G.L., Jensen R.H., Katsarava Z., Stovner L.J., Martelleti P. Headache disorders are third cause of disability worldwide. J. Headache Pain. 2015;16:58. http://dx.doi:10.1186/s10194-015-0544-2Steiner T.J., Birbeck G.L., Jensen R.H., Katsarava Z., Stovner L.J., Martelleti P. Headache disorders are third cause of disability worldwide. J. Headache Pain. 2015;16:58. http://dx.doi:10.1186/s10194-015-0544-2Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545–1602. http://dx.doi:10.1016/S01406736(16)31678-6Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545–1602. http://dx.doi:10.1016/S01406736(16)31678-6Tietjen G.E., Collins S.A. Hypercoagulability and migraine. Headache. 2018;58(1):173–183. http://dx.doi:10.1111/head.13044Tietjen G.E., Collins S.A. Hypercoagulability and migraine. Headache. 2018;58(1):173–183. http://dx.doi:10.1111/head.13044Bakar N.A., Tanprawate S., Lambru G., Torkamani M., Jahanshahi M., Matharu M. Quality of life in primary headache disorders: A review. Cephalalgia. 2016;36(1):67–91. http://dx.doi:10.1177/0333102415580099Bakar N.A., Tanprawate S., Lambru G., Torkamani M., Jahanshahi M., Matharu M. Quality of life in primary headache disorders: A review. Cephalalgia. 2016;36(1):67–91. http://dx.doi:10.1177/0333102415580099Филатова Е.Г., Осипова В.В., Табеева Г.Р., Парфенов В.А., Екушева Е.В., Азимова Ю.Э. и др. Диагностика и лечение мигрени: рекомендации российских экспертов. Неврология, нейропсихиатрия, психосоматика. 2020;4(12):4–14. 2020;12(4):4–14. https://doi.org/10.14412/2074-2711-2020-4-4-14. [Filatova E.G., Osipova V.V., Tabeeva G.R., Parfenov V.A., Ekusheva E.V., Azimova Yu.E., et al. Diagnosis and treatment of migraine: Russian experts’ recommendations. Neurology, Neuropsychiatry, Psychosomatics 2020;12(4):4–14. (Russian). https://doi.org/10.14412/2074-2711-2020-4-4-14Burch R.C., Buse D.C., Lipton R.B. Migraine: epidemiology, burden, and comorbidity. Neurol Clin. 2019;37(4):631–649. http://dx.doi:10.1016/j.ncl.2019.06.001Burch R.C., Buse D.C., Lipton R.B. Migraine: epidemiology, burden, and comorbidity. Neurol Clin. 2019;37(4):631–649. http://dx.doi:10.1016/j.ncl.2019.06.001Наприенко М.В., Смекалкина Л.В., Сафонов М.И., Филатова Е.Г., Латышева Н.В., Екушева Е.В. и др. Бремя мигрени в реальной клинической практике: клиническое и экономические аспекты. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019;119(1):31–37. https://doi.org/10.17116/jnevro201911901131Naprienko M.V., Smekalkina L.V., Safonov M.I., Filatova E.G., Ekusheva E.V., Artemenko A.R., et al. Real-world migraine burden: clinical and economic aspects. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(1):31–37. https://doi.org/10.17116/jnevro201911901131Rivera-Mancilla E., Villalón C.M., MaassenVanDenBrink A. CGRP inhibitors for migraine prophylaxis: a safety review. Expert Opin. Drug Saf. 2020;19(10):1237–1250. https://doi:10.108 0/14740338.2020.1811229Rivera-Mancilla E., Villalón C.M., MaassenVanDenBrink A. CGRP inhibitors for migraine prophylaxis: a safety review. Expert Opin. Drug Saf. 2020;19(10):1237–1250. https://doi:10.108 0/14740338.2020.1811229Edvinsson L. Role of CGRP in migraine. Handb Exp Pharmacol. 2019;255:121–30. https://doi.org/10.1007/164_2018_201Edvinsson L. Role of CGRP in migraine. Handb Exp Pharmacol. 2019;255:121–30. https://doi.org/10.1007/164_2018_201Mitsikostas D.D., Reuter U. Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies. Curr. Opin. Neurol. 2017;30(3):272–280. https://doi:10.1097/WCO.0000000000000438Mitsikostas D.D., Reuter U. Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies. Curr. Opin. Neurol. 2017;30(3):272–280. https://doi:10.1097/WCO.0000000000000438Masoud A.T., Hasan M.T., Sayed A., Edward H.N., Amer A.M., Naga A.E., et al. Efficacy of calcitonin gene-related peptide (CGRP) receptor blockers in reducing the number of monthly migraine headache days (MHDs): A network meta-analysis of randomized controlled trials. J. Neurol. Sci. 2021;427:117505. https://doi.org/10.1016/j.jns.2021.117505.Masoud A.T., Hasan M.T., Sayed A., Edward H.N., Amer A.M., Naga A.E., et al. Efficacy of calcitonin gene-related peptide (CGRP) receptor blockers in reducing the number of monthly migraine headache days (MHDs): A network meta-analysis of randomized controlled trials. J. Neurol. Sci. 2021;427:117505. https://doi.org/10.1016/j.jns.2021.117505.Deng H., Li G.-G., Nie H., Feng Y.-Y., Guo G.-Y., Guo W.-L. et al. Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine — an updated systematic review and meta-analysis. BMC Neurol. 2020;20(1):57. https://doi:10.1186/s12883-02001633-3Deng H., Li G.-G., Nie H., Feng Y.-Y., Guo G.-Y., Guo W.-L. et al. Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine — an updated systematic review and meta-analysis. BMC Neurol. 2020;20(1):57. https://doi:10.1186/s12883-02001633-3Sacco S., Bendtsen L., Ashina M., Reuter U., Terwindt G., Mitsikostas D.D. et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J. Headache Pain. 2019;20(1):6. https://doi:10.1186/s10194-0180955-y.PMID: 30651064Sacco S., Bendtsen L., Ashina M., Reuter U., Terwindt G., Mitsikostas D.D. et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J. Headache Pain. 2019;20(1):6. https://doi:10.1186/s10194-0180955-y.PMID: 30651064Zhu C., Guan J., Xiao H., Luo W., Tong R. Erenumab safety and efficacy in migraine: A systematic review and meta-analysis of randomizedclinicaltrials.Medicine(Baltimore).2019;98(52):e18483. https://doi:10.1097/MD.0000000000018483Zhu C., Guan J., Xiao H., Luo W., Tong R. Erenumab safety and efficacy in migraine: A systematic review and meta-analysis of randomizedclinicaltrials.Medicine(Baltimore).2019;98(52):e18483. https://doi:10.1097/MD.0000000000018483Bucklan J., Ahmed Z. CGRP antagonists for decreasing migraine frequency: new options, long overdue. Cleve Clin. J. Med. 2020;87(4):211–218. https://doi:10.3949/ccjm.87a.19048.Bucklan J., Ahmed Z. CGRP antagonists for decreasing migraine frequency: new options, long overdue. Cleve Clin. J. Med. 2020;87(4):211–218. https://doi:10.3949/ccjm.87a.19048.Chang C.L., Hsu S.Y.T. PLoS One. Development of chimeric and bifunctional antagonists for CLR/RAMP receptors. 2019;14(5):e0216996. https://doi:10.1371/journal.pone.0216996Chang C.L., Hsu S.Y.T. PLoS One. Development of chimeric and bifunctional antagonists for CLR/RAMP receptors. 2019;14(5):e0216996. https://doi:10.1371/journal.pone.0216996Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211. https://doi:10.1177/0333102417738202Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211. https://doi:10.1177/0333102417738202Buse D.C., Greisman J.D., Baigi K., Lipton R.B. Migraine progression: a systematic review. Headache. 2019;59(3):306–338. https://doi:10.1111/head.13459Buse D.C., Greisman J.D., Baigi K., Lipton R.B. Migraine progression: a systematic review. Headache. 2019;59(3):306–338. https://doi:10.1111/head.13459Ashina M., Goadsby P.J., Reuter U., Silberstein S., Dodick D.W., Xue F. et al. Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur. J. Neurol. 2021;28(5):1716–1725. https://doi:10.1111/ene.14715Ashina M., Goadsby P.J., Reuter U., Silberstein S., Dodick D.W., Xue F. et al. Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur. J. Neurol. 2021;28(5):1716–1725. https://doi:10.1111/ene.14715Raffaelli B., Kalantzis R., Mecklenburg J., Overeem L.H., Neeb L., Gendolla A., et al. Erenumab in chronic migraine patients who previously failed five first-line oral prophylactics and onabotulinumtoxinA: a dual-center retrospective observational study. Fronties in Neurology. 2020;11:417. https://doi.org/10.3389/fneur.2020.00417Raffaelli B., Kalantzis R., Mecklenburg J., Overeem L.H., Neeb L., Gendolla A., et al. Erenumab in chronic migraine patients who previously failed five first-line oral prophylactics and onabotulinumtoxinA: a dual-center retrospective observational study. Fronties in Neurology. 2020;11:417. https://doi.org/10.3389/fneur.2020.00417Tepper S., Ashina M., Reuter U., Brandes J.L., Doležil D., Silberstein S. et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebocontrolled phase 2 trial. Lancet Neurology. 2017;16(6):425–434. https://doi.org/10.1016/S1474-4422(17)30083-2Tepper S., Ashina M., Reuter U., Brandes J.L., Doležil D., Silberstein S. et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebocontrolled phase 2 trial. Lancet Neurology. 2017;16(6):425–434. https://doi.org/10.1016/S1474-4422(17)30083-2Lambru G., Hill B., Murphy M., Tylova I., Andreou A.P. A prospective real-world analysis of erenumab in refractory chronic migraine. The Journal of Headache and Pain. 2020;21(1):61. https://doi.org/10.1186/s10194-020-01127-0Lambru G., Hill B., Murphy M., Tylova I., Andreou A.P. A prospective real-world analysis of erenumab in refractory chronic migraine. The Journal of Headache and Pain. 2020;21(1):61. https://doi.org/10.1186/s10194-020-01127-0

The authors declare that there are no conflicts of interest present.